Hepion Pharmaceuticals Initiates Wind-Down Activities In Phase 2b ‘ASCEND-NASH’ Trial
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic